NewAmsterdam Pharma Company N.V. (NAMS)
| Market Cap | 3.30B |
| Revenue (ttm) | 22.50M |
| Net Income (ttm) | -203.82M |
| Shares Out | 114.98M |
| EPS (ttm) | -1.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,452,771 |
| Open | 30.45 |
| Previous Close | 30.45 |
| Day's Range | 27.85 - 30.96 |
| 52-Week Range | 16.79 - 42.00 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 46.75 (+62.78%) |
| Earnings Date | May 6, 2026 |
About NAMS
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere... [Read more]
Financial Performance
In 2025, NAMS's revenue was $22.50 million, a decrease of -50.61% compared to the previous year's $45.56 million. Losses were -$203.82 million, -15.64% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $46.75, which is an increase of 62.78% from the latest price.
News
NewAmsterdam Pharma Company Transcript: 25th Annual Needham Virtual Healthcare Conference
Recent phase III data show strong LDL and MACE benefits, with additional advantages in diabetes and Alzheimer's biomarkers. U.S. and E.U. launches are on track, supported by robust financials and expanded leadership. Market opportunity is growing with new guidelines and broad clinical differentiation.
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, April 08, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical comp...
NewAmsterdam Pharma Company Transcript: Leerink Global Healthcare Conference 2026
Obicetrapib has shown strong LDL and Lp(a) lowering in phase III trials, with European approval and major outcome data expected this year. Commercial prospects are robust, with label expansion in diabetes and Alzheimer's prevention studies underway, and significant differentiation from competitors.
NewAmsterdam Pharma Company Transcript: TD Cowen 46th Annual Health Care Conference
Obicetrapib has shown robust LDL and Lp(a) lowering, strong tolerability, and a 21% MACE reduction in Phase III trials. Commercial launch in Europe is planned for late 2024, with PREVAIL outcomes data expected to drive U.S. uptake. Alzheimer's prevention and diabetes risk reduction are key differentiators.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAARDEN, the Netherlands and MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking i...
NewAmsterdam Pharma Company Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
PREVAIL and BROADWAY studies show aligned event rates, supporting confidence in outcomes. Obicetrapib stands out for its broad efficacy, safety, and convenience, with regulatory milestones expected in Europe and the U.S. this year. Commercial strategy targets a large, underserved population.
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
-- EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combo expected in 2H26 -- -- Phase 3 PREVAIL CVOT overall event rate tracking in line with observed rate in BROADWAY --
NewAmsterdam Pharma Company Transcript: Piper Sandler 37th Annual Healthcare Conference
Record attendance marked the 37th annual conference, with major updates on cardiovascular trials and regulatory progress. PREVAIL CVOT and other key studies are on track for 2026, while commercial strategies focus on maximizing launch impact and product differentiation.
NewAmsterdam Pharma Company Transcript: Citi Annual Global Healthcare Conference 2025
Obicetrapib demonstrated strong efficacy in lowering LDL and Lp(a), reducing diabetes risk, and showing Alzheimer's biomarker benefits, with robust phase 3 and ongoing PREVAIL studies supporting regulatory and commercial plans. Market positioning is strengthened by broad medical support, a major European partnership, and a focus on payer value.
NewAmsterdam Pharma Company Transcript: Evercore ISI 8th Annual HealthCONx Conference
Three positive phase III studies support regulatory filings in Europe, with U.S. launch dependent on PREVAIL outcomes. Obicetrapib is positioned as a differentiated CETP inhibitor targeting broad patient populations, with a focus on payer access and a strong safety profile. Market opportunity is estimated above $5 billion, with plans for further Alzheimer’s research.
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NAARDEN, The Netherlands and MIAMI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Company Transcript: Jefferies London Healthcare Conference 2025
Obicetrapib is advancing toward a 2024 European launch, with the pivotal PREVAIL CVOT trial expected to deliver key data by late 2026 or early 2027. The drug differentiates itself through broad metabolic benefits, high goal attainment, and a strong IP position, while the expanding market offers room for multiple oral therapies.
NewAmsterdam Pharma Company Transcript: Stifel 2025 Healthcare Conference
Recent clinical data support broader LDL lowering and expanded treatment populations, with PREVAIL and BROADWAY trials showing strong efficacy and additional benefits. Obicetrapib is positioned for significant commercial opportunity and further development in Alzheimer's, with regulatory and launch milestones on track.
NewAmsterdam Pharma Company Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Recent clinical data support aggressive LDL lowering for a broader high-risk population, with guidelines expected to shift and the market for lipid therapies expanding. Obicetrapib is positioned for strong uptake due to its added benefits and ease of use, with key trial readouts and regulatory milestones anticipated through 2027.
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
– Marketing Authorization Applications for obicetrapib and FDC of obicetrapib plus ezetimibe accepted for review by European Medicines Agency –
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
NAARDEN, The Netherlands and MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical compa...
NewAmsterdam Pharma Company Transcript: Stifel Virtual Cardiometabolic Forum
PREVAIL, a large outcomes trial, is fully enrolled and on track, aiming to confirm the 21% MACE reduction seen in prior studies. Regulatory filings are progressing in Europe and the U.S., with commercial launch planned alongside outcomes data. Obicetrapib differentiates itself through efficacy, safety, and potential benefits in Alzheimer’s biomarkers.
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The company expects EU approval and launch of its LDL-lowering therapy within 12 months, with strong efficacy in LDL and Lp(a) reduction and additional benefits for diabetes and Alzheimer's risk. PREVAIL outcome study is on track, supporting a broad US label and global market potential exceeding $8B.
NewAmsterdam Pharma Company Transcript: Cantor Global Healthcare Conference 2025
Obicetrapib’s regulatory and clinical progress is advancing globally, with a strong focus on outcome-driven approvals and combination therapies. The drug’s robust efficacy in lowering LDL, Lp(a), and Alzheimer’s biomarkers, along with a favorable safety profile, positions it for significant market impact, especially as PREVAIL and RUBIN data mature.
NewAmsterdam Pharma Company Transcript: Citi's Biopharma Back to School Conference
Phase III data show robust LDL lowering, safety, and significant MACE reduction, with additional benefits in diabetes and Alzheimer's biomarkers. The drug is positioned for broad adoption, supported by strong clinical evidence, strategic partnerships, and a focus on combination therapies.